Stephanie Dusaban Gonzales Ph.D.

Dr. Stephanie Dusaban Gonzales is an associate in Goodwin’s Life Sciences group. She has been practicing for six years and has over ten years of biomedical research experience in pharmacology, cell signaling, drug discovery, and translational medicine. She has extensive experience in leading patent prosecution, diligence, and related transactions, including capital raising, licensing, and initial public offerings.

Stephanie works extensively in the life sciences space, representing growth-stage therapeutics companies relating to pharmacology, antibody therapies, cell therapies, peptide-based therapeutics, CRISPR and genetic engineering, gene therapies, agriculture, and synthetic DNA tools. She manages patent strategy and prosecution of US and foreign patents for private and public companies. She has led IP diligence on both client-side capital raises and investor-side on investments totaling over $300 million.

Prior to joining Goodwin, Stephanie was an associate at Wilson Sonsini Goodrich Rosati, and previously a patent agent at Wilson Sonsini Goodrich Rosati. Stephanie also worked as a postdoctoral fellow at the University of California, San Diego, investigating receptor signaling relating to inflammation in the Central Nervous System.

• Author, "Sphingosine 1-Phosphate Receptor 3 and RhoA Signaling Mediate Inflammatory Gene Expression in Astrocytes. J. Neuroinflammation," 2017
• Author, "Thrombin Promotes Sustained Signaling and Inflammatory Gene Expression through the CDC25 and Ras Associating Domains of Phospholipase C-epsilon," 2015
• Author, "PLCε Mediated Sustained Signaling Pathways," 2015
• Author, "Phospholipase C-epsilon Links G-protein Coupled Receptor Activation to Inflammatory Astrocytic Responses," 2013
• Co-Author, "Lysophospholipid Receptor Activation of RhoA and Lipid Signaling Pathways, 1831 Biochimica et Biophysica Acta," 2012
• Co-Author, "The c-Myb Gene Target Neuromedin U Functions as a Novel Cofactor during the Early Stages of Erythropoiesis," 2011